A XM não fornece serviços a residentes nos Estados Unidos da América.

A XM não fornece serviços a residentes nos Estados Unidos da América.
A
A

Abbott

Notícias

Reuters - Há 1 semana

Abbott India gains on upbeat Q1 results

BUZZ-Abbott India gains on upbeat Q1 results ** Shares of Abbott India ABOT.NS climb ~4% to 29,139.30 rupees, their highest since February ** Drugmaker reports 13% Y/Y rise in Q1 consol net profit ; 5.3% Y/Y rev growth ** Stock top pct gainer in pharma index .NIPHARM , which is up ~1% ** Trading volume 2.4x the 30-day moving average ** ABOT among 1
A
Reuters - Há 1 semana

India economic, corporate events on August 8

DIARY- India economic, corporate events on August 8 BENGALURU, Aug 8 (Reuters) - Diary of India economic, corporate events on August 8. ECONOMIC, CORPORATE .BSE500 EVENTS: RIC Local Start Date Local Time Indicator Name Period Reuters Poll Prior INREPO=ECI 8 Aug 2024 10:00 Repo Rate 8 Aug 6.50% 6.50% INRREP=ECI 8 Aug 2024 10:00 Reverse Repo Rate 8 A
A
A
A
B
B
Reuters - Há 1 semana

U.S. STOCKS Abbott Laboratories, Medtronic, Axon

BUZZ-U.S. STOCKS ON THE MOVE-Abbott Laboratories, Medtronic, Axon Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes advanced on Wednesday, aided by a dovish turn by Japan's top policymaker after a surprise interest rate hike last week which partly sparked heavy volatility in global markets.
A
A
C
F
I
T
U
U
L
Reuters - Há 1 semana

Some diabetes device makers fall after Abbott, Medtronic glucose monitoring partnership

BUZZ-Some diabetes device makers fall after Abbott, Medtronic glucose monitoring partnership ** Shares of Tandem diabetes care TNDM.O fall ~9.9% to $39.17 ** Medical device makers Abbott Laboratories ABT.N and Medtronic MDT.N have entered into a partnership to integrate the former's continuous glucose monitoring (CGM) sensors with MDT's insulin del
A
C
Reuters - Há 1 semana

Abbott, Medtronic rise on glucose monitoring partnership

BUZZ-Abbott, Medtronic rise on glucose monitoring partnership Updates ** Shares of medical device makers Abbott Laboratories ABT.N rise 1.7% to $111.36 and Medtronic MDT.N r ise 1.8% to $82 .24 ** ABT says it has entered into a global partnership with MDT to integrate the former's continuous glucose monitoring (CGM) sensors with MDT's insulin deliv
A
Reuters - Há 1 semana

Abbott, Medtronic rise on glucose monitoring partnership

BUZZ-Abbott, Medtronic rise on glucose monitoring partnership ** Shares of medical device makers Abbott Laboratories ABT.N and Medtronic MDT.N rise 2.3% to $112.03 and $82.64, respectively ** ABT says it has entered into a global partnership with MDT to integrate the former's continuous glucose monitoring (CGM) sensors with MDT's insulin delivery s
A
Reuters - Há 1 semana

Drugmaker Abbott India's Q1 profit climbs on higher sales, price hikes

Drugmaker Abbott India's Q1 profit climbs on higher sales, price hikes BENGALURU, Aug 7 (Reuters) - Drugmaker Abbott India ABOT.NS reported a rise in first-quarter profit on Wednesday, helped by higher sales and price hikes. The company, which makes the popular antacid medicine Digene, said its profit rose to 3.28 billion rupees ($39.1 million) for the quarter ended June 30, a 13% rise from last year.
A
G
P
Reuters - Há 1 semana

India economic, corporate events on August 7

DIARY- India economic, corporate events on August 7 BENGALURU, Aug 7 (Reuters) - Diary of India economic, corporate events on August 7. ECONOMIC, CORPORATE .BSE500 EVENTS: Key Speaker Local Time Location India commerce minister 0930 BIMSTEC Business Summit, New Delhi India financial services secretary 1000 Industry body FICCI event, New Delhi RIC Local Start Date Local Time Indicator Name Period Reuters Poll Prior INM3MS=ECI 7 Aug 2024 17:00 M3 Money Supply 26 Jul, w/e 10.7% Start Date Start Tim
A
B
C
Reuters - Há 2 semanas

India's GlaxoSmithKline Pharma posts higher Q1 adjusted profit on strong demand

India's GlaxoSmithKline Pharma posts higher Q1 adjusted profit on strong demand BENGALURU, Aug 2 (Reuters) - India's GlaxoSmithKline Pharmaceuticals GLAX.NS reported a higher first-quarter adjusted profit on Friday, driven by strong demand for its generic drugs and vaccines. The Indian unit of British drugmaker GSK GSK.L reported a consolidated profit before tax and exceptional items of 2.49 billion rupees ($29.7 million) for the quarter ended June 30, compared with a profit of 1.64 billion rupe
A
G
P
Reuters - Há 2 semanas

Becton Dickinson tops profit estimates on demand for drug-delivery devices

Becton Dickinson tops profit estimates on demand for drug-delivery devices Aug 1 (Reuters) - Becton Dickinson BDX.N reported a better-than-expected third -quarter profit on Thursday , helped by strong demand for its drug-delivery devices. Medical technology firms such as Becton, Boston Scientific BSX.N and Abbott Laboratories ABT.N are benefiting from a boost in demand as more people, especially older patients, catch up on surgeries that were put on hold during the pandemic.
A
B
Reuters - Há 2 semanas

S&P 500 barely rises as investors await key results, jobs data, Fed meeting

US STOCKS-S&P 500 barely rises as investors await key results, jobs data, Fed meeting Tesla rallies after Morgan Stanley adds stock to 'top pick' list McDonald's rises on strong up-take of $5-meal deal Crypto stocks reverse earlier gains Indexes: Dow off 0.12%, S&P up 0.08%, Nasdaq up 0.07% Updates with closing prices, data By Sinéad Carew and Ankika Biswas July 29 (Reuters) - The S&P 500 c losed barely higher after Monday's choppy trading session as investors h eld their breath ahead of a raft
A
A
A
M
T
U
U
U
Reuters - Há 2 semanas

S&P 500 rises slightly ahead of key results, data, Fed meeting

US STOCKS-S&P 500 rises slightly ahead of key results, data, Fed meeting Adds preliminary closing prices at 4 p.m ET/ 2000 GMT By Sinéad Carew and Ankika Biswas July 29 (Reuters) - The S&P 500 c losed up slightly after Monday's choppy trading as investors anxiously awaited a raft of technology company earnings, a Federal Reserve policy decision on interest-rate cuts and key US labor data, all due this week.
A
A
A
M
T
U
U
U
Reuters - Há 2 semanas

U.S. indexes up in choppy session ahead of key results and data, Fed meeting

US STOCKS-U.S. indexes up in choppy session ahead of key results and data, Fed meeting Tesla up after Morgan Stanley adds stock to 'top pick' list McDonald's jumps on $5-meal deal beat Crypto stocks fall, Abbott drops after formula verdict Indexes: Dow off 0.02%, S&P up 0.15%, Nasdaq up 0.15% Updated prices at 2:29 p.m ET/ 1829 GMT By Sinéad Carew and Ankika Biswas July 29 (Reuters) - The Nasdaq and S&P 500 edged higher on Monday in choppy trading as investors anxiously awaited a raft of techno
A
A
A
M
T
U
U
U
Reuters - Há 2 semanas

U.S. STOCKS Bank of Marin Bancorp, ON Semiconductor, Walt Disney

BUZZ-U.S. STOCKS ON THE MOVE-Bank of Marin Bancorp, ON Semiconductor, Walt Disney Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The Nasdaq and the S&P 500 rose in choppy, range-bound trading on Monday as investors looked forward to a raft of upcoming triggers such as Big Tech earnings, a Federal Reserve policy decision on interest-rate cuts and key labor data.
A
A
A
C
N
T
O
U
U
Reuters - Há 2 semanas

U.S. STOCKS Ventyx Biosciences, McDonald's, Pinterest

BUZZ-U.S. STOCKS ON THE MOVE-Ventyx Biosciences, McDonald's, Pinterest Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The Nasdaq and the S&P 500 rose on Monday, buoyed by megacap stocks as investors awaited Big Tech results, a Federal Reserve policy decision and crucial labor numbers this week.
A
A
A
N
P
T
O
U
U
Reuters - Há 2 semanas

London's FTSE 100 nudges higher on rate optimism

UPDATE 1-London's FTSE 100 nudges higher on rate optimism For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window FTSE 100 up 0.1%, FTSE 250 off 0.5% Pharma shares lead gains US, UK rate decisions in focus Updated at 1550 GMT By Purvi Agarwal and Shubham Batra July 29 (Reuters) - Britain's FTSE 100 closed slightly higher on Monday, boosted by real estate shares on optimism around interest rate cuts in the U.S.
A
A
A
M
U
Reuters - Há 2 semanas

U.S. STOCKS Tesla, Guardant Health, Abbott Laboratories

BUZZ-U.S. STOCKS ON THE MOVE-Tesla, Guardant Health, Abbott Laboratories Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes were poised for a strong opening on Monday, as investors geared up for a Federal Reserve interest-rate decision, along with Big Tech earnings and crucial labor numbers after the recent equity sell-off.
A
A
N
P
T
O
U
Reuters - Há 2 semanas

Futures rise as Fed verdict, Big Tech results expected this week

US STOCKS-Futures rise as Fed verdict, Big Tech results expected this week For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window. Futures up: Dow 0.27%, S&P 500 0.28%, Nasdaq 0.44% July 29 (Reuters) - U.S. index futures climbed on Monday after the recent market rout, as investors girded up for a busy week marked by a Federal Reserve interest-rate decision, eagerly awaited tech earnings and crucial labor data.
A
A
A
G
M
T
U
U
U
Reuters - Há 2 semanas

Abbott shares slide after trial verdict, weigh on rival Reckitt Benckiser

UPDATE 2-Abbott shares slide after trial verdict, weigh on rival Reckitt Benckiser Adds Reckitt statement in paragraph 10 July 29 (Reuters) - Abbott Laboratories' ABT.N shares fell nearly 7% premarket, while British peer Reckitt Benckiser RKT.L slumped 9% on Monday, after the U.S. healthcare firm was ordered to pay $495 million in damages related to its formula for premature infants.
A
Reuters - Há 2 semanas

Abbott slides after co to pay $495 mln in premature infant formula trial

BUZZ-Abbott slides after co to pay $495 mln in premature infant formula trial ** Shares of Abbott ABT.N down 7.1% to $97.76 premarket ** A jury found Abbott's specialized formula for premature infants caused an Illinois girl to develop a dangerous bowel disease, ordering co to pay $495 mln in damages ** The verdict state court comes in the first tr
A

Condições

Ativos populares

Isenção de Responsabilidade: As entidades do XM Group proporcionam serviço de apenas-execução e acesso à nossa plataforma online de negociação, permitindo a visualização e/ou uso do conteúdo disponível no website ou através deste, o que não se destina a alterar ou a expandir o supracitado. Tal acesso e uso estão sempre sujeitos a: (i) Termos e Condições; (ii) Avisos de Risco; e (iii) Termos de Responsabilidade. Este, é desta forma, fornecido como informação generalizada. Particularmente, por favor esteja ciente que os conteúdos da nossa plataforma online de negociação não constituem solicitação ou oferta para iniciar qualquer transação nos mercados financeiros. Negociar em qualquer mercado financeiro envolve um nível de risco significativo de perda do capital.

Todo o material publicado na nossa plataforma de negociação online tem apenas objetivos educacionais/informativos e não contém — e não deve ser considerado conter — conselhos e recomendações financeiras, de negociação ou fiscalidade de investimentos, registo de preços de negociação, oferta e solicitação de transação em qualquer instrumento financeiro ou promoção financeira não solicitada direcionadas a si.

Qual conteúdo obtido por uma terceira parte, assim como o conteúdo preparado pela XM, tais como, opiniões, pesquisa, análises, preços, outra informação ou links para websites de terceiras partes contidos neste website são prestados "no estado em que se encontram", como um comentário de mercado generalizado e não constitui conselho de investimento. Na medida em que qualquer conteúdo é construído como pesquisa de investimento, deve considerar e aceitar que este não tem como objetivo e nem foi preparado de acordo com os requisitos legais concebidos para promover a independência da pesquisa de investimento, desta forma, deve ser considerado material de marketing sob as leis e regulações relevantes. Por favor, certifique-se que leu e compreendeu a nossa Notificação sobre Pesquisa de Investimento não-independente e o Aviso de Risco, relativos à informação supracitada, os quais podem ser acedidos aqui.

Aviso de risco: O seu capital está em risco. Os produtos alavancados podem não ser adequados para todos. Recomendamos que consulte a nossa Divulgação de Riscos.